

## PRESS RELEASE

**Collectis grants Bayer HealthCare license to use homologous recombination patents**

**Paris, January 12, 2010** – Collectis S.A. (Alternext: ALCLS), the French genome engineering specialist, has announced that Bayer HealthCare, the healthcare subgroup of Bayer, has acquired a license to use Collectis' patent family WO9011354 covering homologous recombination aimed to introduce new features into the genome. This global license includes the use of the Institut Pasteur technology relating to homologous recombination to obtain and utilize certain transgenic animals in pharmaceutical research, in all countries, including Japan. The terms of the contract have not been disclosed.

When Collectis was founded, it was granted exclusive rights to this patent family owned by the Institut Pasteur. The technology covered in these patents represents a breakthrough in genetic recombination and it has since become a useful tool for specific aspects and phases of the drug discovery process.

*"Our licensing strategy is central to our business model and allows us to receive fair payment for the scientific and industrial advancements made possible by this technology. It continues to have a strong influence on the evolution of the company, as demonstrated by Collectis' progress in the last ten years, and is an important component of our future growth strategy",* said Collectis' CEO André Choulika.

**About Collectis S.A.**

Collectis SA is a world pioneer in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in *in vivo* genome surgery addressing the therapeutic, food processing, bioproduction and research sectors. Worldwide, Collectis has entered into more than 50 agreements with major players in the pharmaceutical, biotechnology and agrobiotechnology industries, and has over 20 collaborations with academic research groups. To date, Collectis has raised over €70 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For further information about Collectis, visit our website: [www.collectis.com](http://www.collectis.com)



**Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

**For further information, please contact:**

**Collectis S.A.**

Sylvie Delassus  
Senior VP Corporate Communication  
+ 33 (0)1 41 83 99 00  
[media@collectis.com](mailto:media@collectis.com)

**Alize RP**

Caroline Carmagnol  
+33 (0) 6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)